Adaptimmune Therapeutics Ownership | Who Owns Adaptimmune Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Adaptimmune Therapeutics Ownership Summary


Adaptimmune Therapeutics is owned by 0.32% institutional investors, 0.63% insiders, and 99.05% retail investors. Long focus capital management is the largest institutional shareholder, holding 7.03% of ADAP shares. Edinburgh Worldwide Ord is the top mutual fund, with 2.00% of its assets in Adaptimmune Therapeutics shares.

ADAP Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAdaptimmune Therapeutics0.32%0.63%99.05%
SectorHealthcare Stocks 42.53%10.81%46.67%
IndustryBiotech Stocks 45.24%10.75%44.01%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Long focus capital management18.58M7.03%$2.42M
Ubs group6.67M2.52%$866.76K
Bank of america corp /de/4.65M1.92%$4.53M
Renaissance4.05M1.54%$527.03K
Morgan stanley3.67M1.39%$476.59K
Jane street group2.81M1.06%$364.69M
Acadian asset management1.49M0.56%$186.00K
Empirical finance800.00K0.30%$104.00K
B. riley wealth advisors500.00K0.19%$65.00K
Rathbones group432.82K0.16%$56.27M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Long focus capital management18.58M0.08%$2.42M
Lakeridge wealth management110.40K0.01%$14.35K
Lumbard & kellner114.26K0.01%$14.85K
Empirical finance800.00K0.01%$104.00K
Columbia advisory partners36.73K0.00%$4.78K
B. riley wealth advisors500.00K0.00%$65.00K
Prosperity wealth management19.23K0.00%$2.50K
Xtx topco102.50K0.00%$13.32K
Renaissance4.05M0.00%$527.03K
Bank of america corp /de/4.65M0.00%$4.53M

Top Buyers

HolderShares% AssetsChange
Ubs group6.67M0.00%6.60M
Jane street group2.81M0.00%2.81M
Renaissance4.05M0.00%2.17M
B. riley wealth advisors500.00K0.00%500.00K
Lumbard & kellner114.26K0.01%114.26K

Top Sellers

HolderShares% AssetsChange
Matrix capital management company, lp---37.68M
Ecor1 capital---27.40M
Two seas capital lp---22.58M
Nea management company---17.08M
Baillie gifford---11.82M

New Positions

HolderShares% AssetsChangeValue
Jane street group2.81M0.00%2.81M$364.69M
B. riley wealth advisors500.00K0.00%500.00K$65.00K
Lumbard & kellner114.26K0.01%114.26K$14.85K
Lakeridge wealth management110.40K0.01%110.40K$14.35K
Sg americas securities27.50K-27.50K$4.00K

Sold Out

HolderChange
National bank of canada /fi/-10.00
Farther finance advisors-20.00
Northwestern mutual wealth management-153.00
Transce3nd-175.00
Royal bank of canada-700.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202520-69.23%846,318-99.27%-0.57%8-60.00%1-94.74%
Jun 30, 202564-8.57%115,507,217-0.49%713.22%18-30.77%2017.65%
Mar 31, 20255-93.83%42,678,699-65.69%24.21%2-93.55%2-90.48%
Dec 31, 202479-2.47%124,313,247-18.02%88.30%30-18.92%2140.00%
Sep 30, 202479-1.25%151,643,820-1.46%591.46%3656.52%15-31.82%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Edinburgh Worldwide Ord5.28M2.00%-
Baillie Gifford Global Discovery A Acc3.29M1.28%-20.71K
Baillie Gifford WW Discovery B USD Acc1.59M0.62%-6.22K
JPM Thematics Genetic Thrps C2 Acc USD913.17K0.36%-26.08K
JPM Thematics Genetic Thrps C2 dist USD881.69K0.34%-
Galileo - Biotech Innovation Fund S USD752.46K0.28%-
Mercer Global Small Cap Equity M-5£635.81K0.25%-
Mercer Global Small Cap Equity M-3£484.78K0.19%84.40K
SPDR® Portfolio Developed Wld ex-US ETF296.36K0.11%-
A4Investments SICAV SIF ACCI IlanaA2EURH221.29K0.09%-

Recent Insider Transactions


DateNameRoleActivityValue
Sep 02, 2025Wood Gavin Chief Financial OfficerSell$950.40
Aug 28, 2025Bertrand William C JR Chief Operating OfficerSell$2.09K
Aug 15, 2025Behbahani Ali-Sell$53.11K
Aug 18, 2025Behbahani Ali-Sell$176.06K
Jul 30, 2025EcoR1 Capital, LLC-Sell$2.80M

Insider Transactions Trends


DateBuySell
2025 Q3-7
2025 Q1-17
2024 Q3--
2024 Q2-1
2024 Q1-19

ADAP Ownership FAQ


Who Owns Adaptimmune Therapeutics?

Adaptimmune Therapeutics shareholders are primarily institutional investors at 0.32%, followed by 0.63% insiders and 99.05% retail investors. The average institutional ownership in Adaptimmune Therapeutics's industry, Biotech Stocks , is 45.24%, which Adaptimmune Therapeutics falls below.

Who owns the most shares of Adaptimmune Therapeutics?

Adaptimmune Therapeutics’s largest shareholders are Long focus capital management (18.58M shares, 7.03%), Ubs group (6.67M shares, 2.52%), and Bank of america corp /de/ (4.65M shares, 1.92%). Together, they hold 11.48% of Adaptimmune Therapeutics’s total shares outstanding.

Does Blackrock own Adaptimmune Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Adaptimmune Therapeutics.

Who is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested?

Long focus capital management is Adaptimmune Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.08% of its assets in 18.58M Adaptimmune Therapeutics shares, valued at 2.42M$.

Who is the top mutual fund holder of Adaptimmune Therapeutics shares?

Edinburgh Worldwide Ord is the top mutual fund holder of Adaptimmune Therapeutics shares, with 2.00% of its total shares outstanding invested in 5.28M Adaptimmune Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools